CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2021—Randox introduced its Acusera SARS-CoV-2 Antibody Control with reactive and nonreactive controls for anti SARS-CoV-2 to support assay validation and routine performance monitoring of serological assays for COVID-19. The third-party control is supplied in a liquid, ready-to-use format with a 30-day open vial stability at 2° to 8°C.
Pages: 1 2